Bullous Pemphigoid and Human Leukocyte Antigen (HLA)-DQA1: A Systematic Review.
allele
bullous pemphigoid
dqa1
hla
hla-dqa1
human leukocyte antigen
meta-analysis
mhc
mhc class ii
systematic review
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
11
05
2023
accepted:
03
06
2023
medline:
7
7
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Bullous pemphigoid (BP) is an autoimmune blistering disease that mainly affects the elderly. The human leukocyte antigen (HLA) system is believed to be one of the genetic factors involved in the development of BP. The connection between major histocompatibility complex class II, specifically HLA-DQA1, and BP remains inconclusive. The objective of this review is to find potential associations between BP and HLA-DQA1 alleles, identify the HLA-DQA1 alleles associated with an increased or decreased risk of developing BP, and highlight literature gaps for future research. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used to conduct a literature review. Databases used included PubMed/MEDLINE, Google Scholar, Embase, and Cochrane Library. Only studies written in English and conducted after 2000 that investigated the association between HLA-DQA1 and BP in human subjects were included. Odds ratios were calculated from the data provided in the studies, and a meta-analysis was conducted using Review Manager (The Cochrane Collaboration, London, United Kingdom) and MetaXL (EpiGear International Pty Ltd., Queensland, Australia) software. The systematic review found five eligible studies, and all were included in the meta-analysis. Results show an increased odds for BP in the HLA-DQA1*05:05 loci (odds ratio (OR) = 2.25; 95% confidence interval (CI) = 1.80, 2.80) and decreased odds for BP in the HLA-DQA1*02:01 loci (OR = 0.50; 95% CI = 0.36, 0.70). Further research is needed to confirm these findings and explore the potential clinical implications for personalized medicine approaches in BP patients.
Identifiants
pubmed: 37416040
doi: 10.7759/cureus.39923
pmc: PMC10319936
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e39923Informations de copyright
Copyright © 2023, Hesari et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Dermatol. 2018 Jun;57(6):664-669
pubmed: 29630716
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Clin Exp Dermatol. 2002 Jun;27(4):319-21
pubmed: 12139680
Arq Neuropsiquiatr. 2021 Dec;79(12):1109-1115
pubmed: 34877984
Biomolecules. 2020 Oct 10;10(10):
pubmed: 33050407
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1709-1714
pubmed: 28485892
Br J Dermatol. 2022 Mar;186(3):414-425
pubmed: 34480482
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2007-2015
pubmed: 27599898
Ann Dermatol. 2018 Feb;30(1):8-12
pubmed: 29386826
Iran J Immunol. 2013 Mar;10(1):1-9
pubmed: 23502333
Front Immunol. 2019 Jul 02;10:1506
pubmed: 31312206
Orphanet J Rare Dis. 2021 May 19;16(1):228
pubmed: 34011352
Front Immunol. 2019 Oct 15;10:2327
pubmed: 31749790
J Invest Dermatol. 2018 May;138(5):1201-1204
pubmed: 29203362
J Dermatol. 2018 Sep;45(9):1094-1100
pubmed: 29905389
Int J Immunogenet. 2014 Feb;41(1):1-12
pubmed: 24004450
Annu Rev Genomics Hum Genet. 2013;14:301-23
pubmed: 23875801
J Am Acad Dermatol. 2021 Aug;85(2):501-503
pubmed: 30296540
J Dermatol Sci. 2018 Mar;89(3):258-262
pubmed: 29248402
Nat Rev Immunol. 2018 May;18(5):325-339
pubmed: 29292391
MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(6):101-4, 106
pubmed: 12645839